Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · AVITA Medical, Inc. (RCEL)

AVITA Medical Q3 revenue rises 53% to $26.1 million; full-year guidance raised

Positive Impact 4 of 5 earnings Written later

AVITA Medical reported third-quarter 2026 revenue of $26.1 million, up 53% from $17.1 million a year earlier, and raised its full-year 2026 revenue guidance to $92 million to $94 million. Net loss narrowed to $6.2 million ($0.20 per share) from $13.2 million ($0.46 per share), and the company drew the remaining $10.0 million under its Perceptive Advisors credit facility, which management said led it to conclude that substantial doubt about its ability to continue as a going concern had been alleviated.

Key points

  • Q3 2026 total revenue $26.1 million, up 53% from $17.1 million in Q3 2025
  • Full-year 2026 revenue guidance raised to $92 million to $94 million, from $86 million to $89 million
  • Net loss $6.2 million, or $0.20 per share, versus $13.2 million, or $0.46 per share, a year earlier
  • Cash and marketable securities of approximately $10.5 million at September 30, 2026; total facility borrowings reached $60 million after the $10.0 million draw

The filing

CompanyAVITA Medical, Inc. (RCEL)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:10 PM ET
Accession number0001193125-26-449815

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.